Biogen
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Biogen and other ETFs, options, and stocks.About BIIB
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.
BIIB Key Statistics
Stock Snapshot
As of today, Biogen(BIIB) shares are valued at $194.35. The company's market cap stands at 28.54B, with a P/E ratio of 20.86.
As of 2026-04-29, Biogen(BIIB) stock has fluctuated between $180.18 and $195.89. The current price stands at $194.35, placing the stock +7.9% above today's low and -0.8% off the high.
The Biogen(BIIB)'s current trading volume is 2.45M, compared to an average daily volume of 1.11M.
In the last year, Biogen(BIIB) shares hit a 52-week high of $202.41 and a 52-week low of $115.25.
In the last year, Biogen(BIIB) shares hit a 52-week high of $202.41 and a 52-week low of $115.25.
BIIB News
BofA analyst Jason Zemansky raised the firm’s price target on Biogen (BIIB) to $203 from $200 and keeps a Neutral rating on the shares. The firm views the stren...
AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX AD...
Biogen lowered its earnings guidance and projected weaker revenue for 2026. BRIAN SNYDER / REUTERS Biogen BIIB 1.50 %increase; green up pointing triangle lower...
Analyst ratings
53%
of 38 ratingsMore BIIB News
Full year 2026 total revenue expected to decline by a mid-single digit percentage versus full year 2025. Full year 2026 Non-GAAP diluted EPS is now expected to...
For investors considering whether Biogen's share price reflects its underlying value, the recent mix of long term gains and shorter term pullbacks makes the val...
Biogen BIIB will report first-quarter 2026 results on April 29, before market open. In the last reported quarter, the company's earnings beat expectations by 23...
Biogen (NasdaqGS:BIIB) has acquired exclusive rights to felzartamab in the Greater China Region from TJ Biopharma. The deal consolidates global rights to felza...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.